OA12907A - Use of IKB-kinase inhibitors for the treatment of pain. - Google Patents

Use of IKB-kinase inhibitors for the treatment of pain. Download PDF

Info

Publication number
OA12907A
OA12907A OA1200500046A OA1200500046A OA12907A OA 12907 A OA12907 A OA 12907A OA 1200500046 A OA1200500046 A OA 1200500046A OA 1200500046 A OA1200500046 A OA 1200500046A OA 12907 A OA12907 A OA 12907A
Authority
OA
OAPI
Prior art keywords
alkyl
radical
unsubstituted
substituted
hydrogen atom
Prior art date
Application number
OA1200500046A
Other languages
English (en)
Inventor
Martin Michaelis
Olaf Ritzeler
Gerhard Jaehne
Karl Rudolphi
Gerd Geisslinger
Hans-Georg Schaible
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of OA12907A publication Critical patent/OA12907A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Paper (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
OA1200500046A 2002-08-17 2003-08-05 Use of IKB-kinase inhibitors for the treatment of pain. OA12907A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10237723A DE10237723A1 (de) 2002-08-17 2002-08-17 Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie

Publications (1)

Publication Number Publication Date
OA12907A true OA12907A (en) 2006-10-13

Family

ID=31968975

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200500046A OA12907A (en) 2002-08-17 2003-08-05 Use of IKB-kinase inhibitors for the treatment of pain.

Country Status (34)

Country Link
EP (1) EP1531819B1 (xx)
JP (1) JP4504811B2 (xx)
KR (2) KR101119845B1 (xx)
CN (1) CN100398107C (xx)
AR (1) AR043045A1 (xx)
AT (1) ATE418336T1 (xx)
AU (1) AU2003271555B2 (xx)
BR (1) BR0313555A (xx)
CA (1) CA2495455C (xx)
CO (1) CO5690585A2 (xx)
CR (1) CR7716A (xx)
CY (1) CY1108874T1 (xx)
DE (2) DE10237723A1 (xx)
DK (1) DK1531819T3 (xx)
EC (1) ECSP055609A (xx)
ES (1) ES2320118T3 (xx)
HK (1) HK1079426A1 (xx)
HR (1) HRP20050041B1 (xx)
IL (1) IL166780A (xx)
MA (1) MA27334A1 (xx)
MX (1) MXPA05001218A (xx)
MY (1) MY138059A (xx)
NO (1) NO334309B1 (xx)
OA (1) OA12907A (xx)
PL (1) PL212356B1 (xx)
PT (1) PT1531819E (xx)
RS (1) RS51878B (xx)
RU (1) RU2320338C2 (xx)
SI (1) SI1531819T1 (xx)
TN (1) TNSN05044A1 (xx)
TW (1) TWI325782B (xx)
UA (1) UA80837C2 (xx)
WO (1) WO2004022057A1 (xx)
ZA (1) ZA200500323B (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
WO2006019831A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019832A1 (en) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating hepatitis c
DE102005025225A1 (de) * 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201242962A (en) * 2010-12-01 2012-11-01 Sumitomo Chemical Co Pyrimidine compound and use for pest control thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
RU2631320C2 (ru) 2011-12-06 2017-09-21 Санофи Кристаллические формы [(s)-1-карбамоил-2-(фенилпиримидин-2-иламино)этил]амида 2-(2-метиламинопиримидин-4-ил)-1н-индол-5-карбоновой кислоты
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
CN106535899A (zh) * 2014-07-03 2017-03-22 赛诺菲 用于治疗与骨关节炎相关的疼痛的2‑(2‑甲基氨基‑嘧啶‑4‑基)‑1h‑吲哚‑5‑甲酸[(s)‑1‑氨甲酰基‑2‑(苯基‑嘧啶‑2‑基‑氨基)‑乙基]‑酰胺
AU2019304216B2 (en) 2018-07-16 2022-06-02 Novartis Ag Chemical process for preparing phenylpiperidinyl indole derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE50010931D1 (de) * 1999-06-23 2005-09-15 Aventis Pharma Gmbh Substituierte benzimidazole
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Also Published As

Publication number Publication date
HRP20050041B1 (hr) 2013-07-31
IL166780A (en) 2011-11-30
KR101119845B1 (ko) 2012-02-28
DE50310980D1 (de) 2009-02-05
JP4504811B2 (ja) 2010-07-14
TW200417370A (en) 2004-09-16
UA80837C2 (uk) 2007-11-12
AU2003271555B2 (en) 2009-03-26
NO334309B1 (no) 2014-02-03
ES2320118T3 (es) 2009-05-19
RS20050070A (xx) 2007-06-04
PL373568A1 (en) 2005-09-05
TNSN05044A1 (en) 2007-05-14
DK1531819T3 (da) 2009-04-20
AR043045A1 (es) 2005-07-13
PT1531819E (pt) 2009-02-18
HK1079426A1 (en) 2006-04-07
ECSP055609A (es) 2005-04-18
MXPA05001218A (es) 2005-05-16
HRP20050041A2 (hr) 2006-04-30
KR20110135428A (ko) 2011-12-16
EP1531819A1 (de) 2005-05-25
AU2003271555A1 (en) 2004-03-29
CA2495455C (en) 2011-01-11
MA27334A1 (fr) 2005-05-02
ZA200500323B (en) 2006-02-22
MY138059A (en) 2009-04-30
RU2005107419A (ru) 2005-08-10
EP1531819B1 (de) 2008-12-24
NO20051339L (no) 2005-05-03
BR0313555A (pt) 2005-07-12
WO2004022057A1 (de) 2004-03-18
RS51878B (sr) 2012-02-29
TWI325782B (en) 2010-06-11
RU2320338C2 (ru) 2008-03-27
CN100398107C (zh) 2008-07-02
SI1531819T1 (sl) 2009-06-30
ATE418336T1 (de) 2009-01-15
KR20050058339A (ko) 2005-06-16
CO5690585A2 (es) 2006-10-31
IL166780A0 (en) 2006-01-15
CR7716A (es) 2008-11-25
CN1674899A (zh) 2005-09-28
CY1108874T1 (el) 2014-07-02
CA2495455A1 (en) 2004-03-18
JP2005539053A (ja) 2005-12-22
DE10237723A1 (de) 2004-07-08
PL212356B1 (pl) 2012-09-28

Similar Documents

Publication Publication Date Title
OA12907A (en) Use of IKB-kinase inhibitors for the treatment of pain.
US8809358B2 (en) Use of IκB-kinase inhibitors in pain therapy
EP1261601B1 (de) Substituierte indole zur modulierung von nfkb-aktivität
DE10237722A1 (de) Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
BRPI0721290A2 (pt) Compostos orgânicos
CZ20014526A3 (cs) Substituované benzimidazoly
KR20090098884A (ko) 약제학적 조성물 및 이의 사용방법
JP2008534461A (ja) 置換オキシインドール誘導体、前記誘導体を含む医薬およびそれの使用
NZ538297A (en) Use of IkB kinase inhibitors for the treatment of pain
RU2415134C9 (ru) Способ лечения или профилактики физиологических и/или патофизиологических состояний, опосредуемых рецепторами, стимулирующими секрецию гормона роста, триазолы и фармацевтическая композиция на их основе
DE102004034380A1 (de) Verwendung von TRIAL und IkappaB-Kinase Inhibitoren in der Krebsbehandlung